Novo Nordisk A/S Common Stock (NVO)
59.43
+0.10 (0.17%)
NYSE · Last Trade: Jan 30th, 4:21 PM EST
The target action date for orforglipron is now April 10.
Via The Motley Fool · January 30, 2026
Both companies are trading at attractive valuations today.
Via The Motley Fool · January 28, 2026
The Wegovy maker is coming off a dismal showing in 2025, but it's a legitimate 2026 rebound candidate.
Via The Motley Fool · January 28, 2026
Novo Nordisk stock will ride a wave of demand for Ozempic pills in 2026.
Via The Motley Fool · January 27, 2026
Novo Nordisk In Green After Oral Wegovy Clocks Over 18K Prescriptions In A Weekstocktwits.com
Via Stocktwits · January 23, 2026
There might be massive upside ahead for these drugmakers.
Via The Motley Fool · January 27, 2026
Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.
Via The Motley Fool · January 27, 2026
Both companies may succeed in this industry.
Via The Motley Fool · January 26, 2026
This pharmaceutical giant has recently caught fire, and the stock's run is likely just beginning.
Via The Motley Fool · January 26, 2026
It comes as no surprise that all three of them are capitalizing on relatively new, but game-changing, developments.
Via The Motley Fool · January 24, 2026
The company got some bad news to start 2026.
Via The Motley Fool · January 24, 2026
Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of early 2026, the San Diego-based biotech has transitioned from a promising "dark horse" into a formidable contender challenging the global duopoly of Eli Lilly (NYSE: [...]
Via Finterra · January 23, 2026
This biotech has candidates in late-stage clinical development.
Via The Motley Fool · January 23, 2026
Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally underscores the company's status as the undisputed titan of the large-cap healthcare sector, a position bolstered by
Via MarketMinute · January 22, 2026
Wall Street witnessed a surge in risk-on sentiment today as the Cboe Volatility Index (VIX) fell by over 5%, closing at 15.94. The decline marks a sharp reversal from the "Greenland Chill" that gripped markets earlier this week, providing a clear signal that investors are betting on a stabilization
Via MarketMinute · January 22, 2026
The global financial landscape was thrown into chaos on January 20, 2026, as President Donald Trump intensified his administration’s pursuit of Greenland, issuing a sweeping tariff ultimatum against eight European nations. The announcement, which ties the continuation of transatlantic trade relations to the "complete and total purchase" of the
Via MarketMinute · January 21, 2026
When you find winning stocks, stick with them.
Via The Motley Fool · January 20, 2026
Despite a challenging year, the company has a lot to look forward to in the coming years.
Via The Motley Fool · January 20, 2026
Novo and Aspect have been collaborating since 2023 to develop cellular medicines, and said that the new partnership phase builds on the momentum achieved in the existing collaboration.
Via Stocktwits · January 20, 2026
The past couple of years have been challenging for the company. But this could be the beginning of a new chapter.
Via The Motley Fool · January 20, 2026
WASHINGTON D.C. / NEW YORK — Global financial markets were plunged into a state of "Arctic uncertainty" this Tuesday, January 20, 2026, as U.S. stock futures cratered following a weekend of unprecedented geopolitical brinkmanship. President Donald Trump, marking the one-year anniversary of his second term, has reignited his long-standing ambition
Via MarketMinute · January 20, 2026
In a move that has sent shockwaves through both the halls of the United Nations and the trading floors of Wall Street, President Donald Trump has officially designated the acquisition of Greenland as a "vital pillar" of United States national security. This escalation, coming just one year into his second
Via MarketMinute · January 19, 2026
Via MarketBeat · January 19, 2026
In the opening weeks of 2026, the artificial intelligence industry has moved beyond general-purpose models to a high-stakes "verticalization" phase, with healthcare emerging as the primary battleground. Within days of each other, OpenAI and Anthropic have both unveiled dedicated, HIPAA-compliant clinical suites designed to transform how hospitals, insurers, and life sciences companies operate. These launches [...]
Via TokenRing AI · January 19, 2026
On January 11, 2026, Anthropic, the AI safety and research company, officially unveiled its most significant industry-specific expansion to date: specialized healthcare and life sciences tiers for its flagship Claude 4.5 model family. These new offerings, "Claude for Healthcare" and "Claude for Life Sciences," represent a strategic pivot toward vertical AI solutions, aiming to integrate [...]
Via TokenRing AI · January 19, 2026